Drug intelligence / Profile preview

arbutamine

Development stage
Discontinued
Lead developer
Teva Pharmaceutical
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Intravenous
01

Overview

Arbutamine is a synthetic catecholamine and nonselective beta-adrenergic agonist with weak alpha-1 adrenergic activity. It is primarily used as a pharmacologic cardiac stress agent to mimic the effects of exercise in patients who are unable to perform adequate physical exercise, aiding in the diagnosis of coronary artery disease. Arbutamine increases heart rate (positive chronotropic effect), myocardial contractility (positive inotropic effect), and systolic blood pressure by stimulating beta1-, beta2-, and beta3-adrenergic receptors, with greater selectivity for beta receptors over alpha receptors. The drug is administered intravenously via a closed-loop, computer-controlled delivery system that adjusts infusion based on real-time heart rate feedback[1][2][5][6][8].

Brand names
GenESA
Other names
arbutaminaarbutaminumarbutamine hydrochloridearbutamine HCl
02

Targets

ADRB3 (β3)ADRB1 (β1)ADRB2 (β2)ADRA1A (α1A)

Beyond the preview

Go deeper on arbutamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on arbutamine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call